New drug cocktail shows promise in shrinking tough colon tumors before surgery

NCT ID NCT05706779

Recruiting now Disease control Sponsor: Federation Francophone de Cancerologie Digestive Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether giving two drugs (encorafenib and cetuximab) before surgery can shrink tumors in people with a specific genetic mutation (BRAF V600E) in colon or upper rectal cancer. About 30 participants will receive the drugs for 6 weeks before their planned surgery. The main goal is to see how many tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: encorafenib and cetuximab
What this could lead to: If successful, this approach could shrink tumors before surgery, potentially improving outcomes for people with this specific type of colon cancer.
What could go wrong: This is a small, early-phase trial with only 30 participants. It may not work for everyone, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600E MUTATION POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colorectal cancer colorectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF V600E MUTATION POSITIVE COLORECTAL CANCER

Contacts and locations

Locations

Chu - Hôpital Européen Georges Pompidou
RECRUITING

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.